Scancell Share Discussion Threads

[bermudashorts] 20/4/2023 11:34

marcus,

You may well be right and I can understand your confidence. However, you have stated that the difference between the responses from the patients evaluated in the poster and those in the RNS 'proves that the patients improved by the time of the RNS'.

How so? - all we know is that the poster reported responses on 6 patients, but the RNS reported on 14. In other words, the RNS covered an extra 8 patients with 5 more patients showing stable disease. I'm struggling to see how that proves that the responses of the original 6 had improved over time or indeed how it tells us anything about the responses of the original 6 patients. What am I missing in terms of 'proof'?

[inanaco] 20/4/2023 10:47

review Transgene its basically a similar setting to modi1



you will notice in the control arm after only 6 months 2 patients have already seen a return of the cancer after surgery


advanced HNSCC patients following upfront surgery and adjuvant therapy. Head and Neck patients
were randomized to receive the vaccine immediately after first line treatment in monotherapy (Arm A) or
at relapse (Arm B) in conjunction with standard of care. In both studies, the vaccine was administered
weekly for 6 weeks and a booster dose every three weeks over a year.

[the real lozan] 20/4/2023 10:42

Finally the penny drops -
inane posts = "its pointless repeating my posts ...."

[marcusl2] 20/4/2023 10:37

I disagree Bermuda. Confident that the patients improved which is a tremendously encouraging event.

[inanaco] 20/4/2023 10:33

its pointless repeating my posts ....

its what you cant see is the most significance


""The neoadjuvant sub-study in resectable SCCHN, will comprise two doses of
Modi-1 over 3 weeks and in the Modi-1+ pembrolizumab arm patients will
receive an additional dose of pembrolizumab.""

why is that ?

its first line treatment

[bermudashorts] 20/4/2023 10:29

marcus,

You're not comparing like with like

The poster was referring to just the 6 patients from cohorts 1 and 2 but the RNS refers to 14 patients so the additional responses are likely from new patients.

[marcusl2] 20/4/2023 10:20

Did anyone else notice that Modi appears to be working well?

Re the Scancell poster. It says as of FEB

In the recruited cohorts, the best overall response by RECIST v1.1 included 1 PR (SCCHN), 2 SD and 3 PD. The imaging timepoint in cohort 3 (Modi-1+CPI) was not reached in February 2023.


But in the FEB press release they said
14 patients evaluated; of these 14, one has had a partial response and seven have stable disease.

PD is an increase of at least 20% in the sum of the diameters of viable target lesions

That proves that the patients improved by the time of the RNS.

[marcusl2] 20/4/2023 10:17

I am confident that you will be a millionaire Inan.

[rigga 1] 20/4/2023 09:32

May still get cheaper yet ?

[golcheja] 20/4/2023 09:02

Let’s hope vulpas agrees 50p.

[golcheja] 20/4/2023 09:00

Another poster and price drop to below 15.

[inanaco] 20/4/2023 08:50

1,297,057 still building ....

cheap share

ATB

[panama7] 19/4/2023 17:31

Inane, what's your point the melanoma market is worth billions, what slice of the cake has Scib managed to eat up.

[inanaco] 19/4/2023 17:25

transgene value the head and neck market at over a $1b ....

[inanaco] 19/4/2023 17:18

wow 50% of head and neck are immune deserts

[inanaco] 19/4/2023 17:15

that transgene event just started

[panama7] 19/4/2023 15:13

Gol, Scib has sat on the shelf for 12 years, fair chance that Moditope will do exactly the same but don't worry there will be another serendipitous discovery making it's way onto an RNS.

[golcheja] 19/4/2023 15:09

Wonder how we got caught in the AACR PUMP&dump

[golcheja] 19/4/2023 15:05

Is seems poster was a complete waste of space ,great science not interest, bio is not ready yet for modi platform, maybe they will in years to come. Unlikely any MA sniffing and no big backers finance to complete the ongoing trials without raising cash. Well dilution is inevitable.

[the real lozan] 19/4/2023 14:43

serratia...thanks for the response
nappyrash...."Its not just a phone anymore Loz ..."
That is exactly my point -
For some who CAN see = Its not just a phone anymore ...

[panama7] 19/4/2023 14:43

Looks like the poster presentation went down well, would have been better having a couple of Dolly birds standing there than Lindy by the looks of it. Is Moditope another Scib , great Science but zero interest.

[serratia] 19/4/2023 13:38

TRL

No mobile phone.

[marcusl2] 19/4/2023 13:11

ADCs overtake mAbs in AACR’s first-in-human abstracts

[inanaco] 19/4/2023 11:38

facts are "LOL" .... Rucks failed takeover

i think what confused most was that AACR criteria ... Something new ..

what people watching the boiling kettle will notice ... they don't boil



but sound awesome ...

"the Kettle"

[ruckrover] 19/4/2023 11:29

Inan, Try and stick to the facts - I've never bid 15p for Scancell. What I said was I MIGHT buy sum more IF it drops below 15. It didn't (drop to 15p) so I didn't (buy more).